Global Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market Size (2024 - 2029)

Non Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis

The Global Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market size is estimated at USD 20.66 billion in 2024, and is expected to reach USD 48.46 billion by 2029, growing at a CAGR of 18.58% during the forecast period (2024-2029).

COVID-19 had a significant impact on the market over the pandemic period. As per the Wiley article published in May 2021, considering that immunological dysregulation and inflammation were linked to chronic liver disease (CLD), people with CLD were more likely to experience negative consequences after contracting COVID-19. Initial COVID-19 data also revealed that healthy infected people showed abnormal liver function tests, raising the possibility that COVID-19 was directly responsible for liver damage. Additionally, as per the article published by Wolters Kluwer Journal in November 2022, patients with or without pre-existing liver disease may present with elevated aminotransferases in COVID-19. Hence, COVID-19 significantly impacted the non-alcoholic steatohepatitis therapeutics and diagnostics market due to the liver disease risk among the infected patients. In addition, the demand for non-alcoholic steatohepatitis therapeutics is expected to remain intact due to the increasing focus on liver disease treatment and diagnosis during the post-pandemic period, thereby contributing to the growth of the market over the forecast period.

The major factors driving the market's growth are the increase in the NASH-affected population, the rising global prevalence of diabetic and obese populations, and the increasing awareness about NAFLD/NASH. For instance, as per the Global Liver Institute 2022 update, NASH is a progressive form of nonalcoholic fatty liver disease (NAFLD) and will affect more than 115 million people worldwide in 2021. The same source also reported that an estimated 357 million people will likely be affected by 2030. Also, according to the International Diabetes Federation Diabetes Atlas Tenth edition 2021, in 2021, around 537 million adults worldwide were found to have diabetes, projected to grow to 643 million by 2030 and 783 million by 2045. Such increasing prevalence of diabetes leading to the increase of non-alcoholic fatty liver diseases is expected to drive the demand for NASH diagnostics and therapeutics, thereby contributing to the market's growth.

Also, increased research and development of products by various key market players are anticipated to boost market growth. For instance, as per the report from 2021, an investigator-led Phase II trial investigating AbbVie's nonalcoholic steatohepatitis (NASH) asset cenicriviroc (CVC) in hospitalized COVID-19 patients has so far recruited 45 patients of its 183-participant target. The understanding of the pathogenesis and progression of NASH has evolved, and several promising novel therapies associated with the same are being evaluated.

However, the lack of effective diagnostics for nonalcoholic fatty liver disease (NAFLD) and slow advancements in the therapeutic field restrains the market growth.

Non Alcoholic Steatohepatitis Therapeutics and Diagnostics Industry Segmentation

As per the scope of the report, non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is liver inflammation and damage caused by the buildup of fat in the liver. It is part of a group of conditions called non-alcoholic fatty liver disease (NAFLD). The Non-alcoholic Steatohepatitis Therapeutics and Diagnostics Market is segmented by Product (Therapeutics and Diagnostics(Imaging Techniques, Diagnostic Tests, Biopsy) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.